Aliases & Classifications for Alopecia

MalaCards integrated aliases for Alopecia:

Name: Alopecia 12 74 58 29 6 43 15 71

Classifications:

Orphanet: 58  
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:987
ICD9CM 34 704.0 704.00
MeSH 43 D000505
NCIt 49 C50575
SNOMED-CT 67 56317004
ICD10 32 L65.9
UMLS via Orphanet 72 C0002170
Orphanet 58 ORPHA79364
UMLS 71 C0002170

Summaries for Alopecia

Disease Ontology : 12 A hypotrichosis that is characterized by a loss of hair from the head or body.

MalaCards based summary : Alopecia is related to alopecia universalis congenita and nail disorder, nonsyndromic congenital, 1, and has symptoms including pruritus and exanthema. An important gene associated with Alopecia is SASH1 (SAM And SH3 Domain Containing 1), and among its related pathways/superpathways are Adhesion and Cell adhesion_Endothelial cell contacts by junctional mechanisms. The drugs Acitretin and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include Hair, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Hair loss, also known as alopecia or baldness, refers to a loss of hair from part of the head or body.... more...

Related Diseases for Alopecia

Diseases in the Alopecia family:

Alopecia, Congenital

Diseases related to Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1044)
# Related Disease Score Top Affiliating Genes
1 alopecia universalis congenita 35.1 HR FOXN1 AIRE
2 nail disorder, nonsyndromic congenital, 1 32.7 TP63 AIRE
3 atrichia with papular lesions 32.7 VDR MBTPS2 HR FOXN1 ANTXR1
4 hypotrichosis 11 32.3 RIN2 RBM28 DCAF17
5 hypotrichosis 32.0 VDR MBTPS2 HR GJA1 FOXN1 DCAF17
6 keratosis 31.6 MBTPS2 GJA1 DSP
7 skin disease 31.3 VDR TP63 KRT14 GJA1 DSP
8 ectodermal dysplasia 30.9 TP63 KRT14 DSP AIRE
9 palmoplantar keratosis 30.9 SASH1 MBTPS2 GJA1 DSP
10 pachyonychia congenita 1 30.5 MBTPS2 KRT14 DSP
11 hair disease 30.5 VDR MBTPS2 KRT14 FOXN1 DSP DCAF17
12 anodontia 30.4 TP63 ANTXR1
13 angular cheilitis 30.1 MBTPS2 AIRE
14 premature ovarian failure 1 29.6 TP63 AR AIRE
15 alopecia areata 12.9
16 palmoplantar keratoderma and congenital alopecia 2 12.7
17 alopecia, androgenetic, 1 12.7
18 t-cell immunodeficiency, congenital alopecia, and nail dystrophy 12.7
19 androgenic alopecia 12.7
20 frontal fibrosing alopecia 12.6
21 palmoplantar keratoderma and congenital alopecia 1 12.6
22 alopecia totalis 12.6
23 mandibulofacial dysostosis with alopecia 12.6
24 alopecia, neurologic defects, and endocrinopathy syndrome 12.6
25 central centrifugal cicatricial alopecia 12.5
26 alopecia, congenital 12.5
27 alopecia-mental retardation syndrome 1 12.5
28 alopecia-contractures-dwarfism mental retardation syndrome 12.5
29 alopecia, psychomotor epilepsy, pyorrhea, and mental subnormality 12.5
30 polyposis, skin pigmentation, alopecia, and fingernail changes 12.5
31 diffuse alopecia areata 12.5
32 alopecia-intellectual disability syndrome 12.5
33 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 12.5
34 alopecia areata 1 12.4
35 cancer, alopecia, pigment dyscrasia, onychodystrophy, and keratoderma 12.4
36 alopecia-epilepsy-oligophrenia syndrome of moynahan 12.3
37 odonto onycho dysplasia with alopecia 12.3
38 ichthyosis alopecia eclabion ectropion mental retardation 12.3
39 woodhouse-sakati syndrome 12.2
40 hypergonadotropic hypogonadism and partial alopecia 12.2
41 alopecia areata 2 12.2
42 alopecia, androgenetic, 2 12.2
43 alopecia-mental retardation syndrome 2 12.2
44 alopecia intellectual disability syndrome 2 12.2
45 alopecia-mental retardation syndrome 3 12.2
46 alopecia universalis onychodystrophy vitiligo 12.2
47 alopecia-mental retardation syndrome with convulsions and hypergonadotropic hypogonadism 12.2
48 alopecia, familial focal 12.2
49 ichthyosis with alopecia, eclabium, ectropion, and mental retardation 12.2
50 genetic alopecia 12.1

Graphical network of the top 20 diseases related to Alopecia:



Diseases related to Alopecia

Symptoms & Phenotypes for Alopecia

UMLS symptoms related to Alopecia:


pruritus, exanthema

GenomeRNAi Phenotypes related to Alopecia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 10.2 GJA1 SASH1
2 Decreased viability GR00402-S-2 10.2 AHSG AIRE ANTXR1 AR AUTS2 CLDN1
3 Mildly decreased CFP-tsO45G cell surface transport GR00360-A-1 9.73 AHSG AIRE ANTXR1 AR DCAF17 DSP
4 no effect GR00402-S-1 9.62 AHSG AIRE ANTXR1 AR AUTS2 CLDN1

MGI Mouse Phenotypes related to Alopecia:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.35 AHSG AIRE ANTXR1 AR AUTS2 CLDN1
2 cellular MP:0005384 10.33 ANTXR1 AR AUTS2 DCAF17 DSP EDNRA
3 cardiovascular system MP:0005385 10.3 ANTXR1 AR AUTS2 DSP EDNRA FOXN1
4 endocrine/exocrine gland MP:0005379 10.24 AIRE ANTXR1 AR AUTS2 EDNRA FOXN1
5 craniofacial MP:0005382 10.19 ANTXR1 AR DSP EDNRA GJA1 HR
6 mortality/aging MP:0010768 10.17 AIRE ANTXR1 AR AUTS2 CLDN1 DSP
7 embryo MP:0005380 10.16 AR AUTS2 DSP EDNRA FOXN1 GJA1
8 immune system MP:0005387 10.14 AIRE ANTXR1 AR EDNRA FOXN1 GJA1
9 digestive/alimentary MP:0005381 10.13 AIRE AR DSP EDNRA HR KRT14
10 hematopoietic system MP:0005397 10.13 AIRE AR EDNRA FOXN1 GJA1 HR
11 integument MP:0010771 10.11 AR CLDN1 DSP EDNRA FOXN1 GJA1
12 hearing/vestibular/ear MP:0005377 10 AHSG EDNRA FOXN1 GJA1 HR KRT14
13 muscle MP:0005369 9.86 AHSG AR DSP EDNRA FOXN1 GJA1
14 neoplasm MP:0002006 9.76 AIRE ANTXR1 AR AUTS2 FOXN1 HR
15 reproductive system MP:0005389 9.65 AIRE ANTXR1 AR DCAF17 FOXN1 GJA1
16 skeleton MP:0005390 9.28 AHSG ANTXR1 AR AUTS2 EDNRA FOXN1

Drugs & Therapeutics for Alopecia

Drugs for Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 408)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
2
Hydroxychloroquine Approved Phase 4 118-42-3 3652
3
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
4
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
5
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
6
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
7
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
8 Orange Approved Phase 4
9
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
10
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
11 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
12
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
13
Drospirenone Approved Phase 4 67392-87-4 68873
14
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
15
Warfarin Approved Phase 4 81-81-2 6691 54678486
16
Dalteparin Approved Phase 4 9005-49-6
17
Phylloquinone Approved, Investigational Phase 4 84-80-0
18 fluindione Approved, Investigational Phase 4 957-56-2
19
Rivaroxaban Approved Phase 4 366789-02-8
20
Tofacitinib Approved, Investigational Phase 4 477600-75-2
21
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
22
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
23
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
24
Gemcitabine Approved Phase 4 95058-81-4 60750
25
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
27
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
28
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
29
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
30
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
31
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
32
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
33
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
34 Menaquinone Investigational Phase 4 1182-68-9
35 Keratolytic Agents Phase 4
36 Interferon Inducers Phase 4
37 Anti-Infective Agents, Local Phase 4
38 Neuroprotective Agents Phase 4
39 Anti-Asthmatic Agents Phase 4
40 Respiratory System Agents Phase 4
41 Betamethasone benzoate Phase 4
42 Betamethasone Valerate Phase 4 2152-44-5
43 Betamethasone sodium phosphate Phase 4
44 Betamethasone-17,21-dipropionate Phase 4
45 Methylprednisolone Acetate Phase 4
46 Anticoagulants Phase 4
47 Drospirenone and ethinyl estradiol combination Phase 4
48 Fenugreek seed meal Phase 4
49 Fenugreek Phase 4
50 Antithrombins Phase 4

Interventional clinical trials:

(show top 50) (show all 441)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
2 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
3 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
4 Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
5 Combined Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata A Randomized Controlled Trial Completed NCT03535233 Phase 4 Triamcinolone Acetonide;Minoxidil 5 % Topical Spray;clobetasol propionate
6 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
7 Phenotype and Cytokine Production Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Aldara 5% Cream Using Flow Cytometry Completed NCT00176943 Phase 4 Aldara Cream 5%
8 A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
9 Perifollicular Nerves in Alopecia Areata: Response to Topical Capsaicin Completed NCT00176969 Phase 4 Capsaicin
10 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
11 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
12 Minoxidil in Treatment of Androgenetic Alopecia Completed NCT04090801 Phase 4 Topical minoxidil 5% in 90% ethanol and 5% propylene glycol;Topical minoxidil 5% in pure ethanol alone
13 Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients Completed NCT00969462 Phase 4 Doxorubicin
14 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
15 Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
16 The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa. Completed NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
17 Open Label Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Recruiting NCT03422640 Phase 4 Apremilast
18 An Open-label Pilot Study to Investigate the Efficacy of Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Recruiting NCT03521687 Phase 4 Apremilast
19 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Recruiting NCT03388840 Phase 4
20 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Recruiting NCT03800979 Phase 4 Tofacitinib
21 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
22 Study of the Relationship Between the Pharmacokinetics of Vismodegib and Safety Data: a Pilot Study to Therapeutic Optimization in Patients With Basal Cell Carcinoma - OPTIVISMO-1 Recruiting NCT03610022 Phase 4 Treatment with vismodegib
23 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
24 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
25 Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer Active, not recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
26 Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation Not yet recruiting NCT03473600 Phase 4 Triamcinolone acetonide injection
27 Efficacy of Fractional CO2 Laser Alone and as Transepidermal Drug Delivery for Different Modalities of Treatment in Alopecia Areata Not yet recruiting NCT04003376 Phase 4 Triamcinolone Acetonide 10mg/mL;vitamin D solution
28 A Phase 4 Multicenter, Randomized, Placebo Controlled Trial of 3 Doses of Intralesional Triamcinolone (KENALOG®) In the Treatment of Mild to Moderate Patch Type Alopecia Areata Terminated NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
29 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
30 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
31 CT-2103 vs Docetaxel for the Second-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): A Phase III Study Unknown status NCT00054184 Phase 3 docetaxel;paclitaxel poliglumex
32 TREATMENT OF THE RECESSIVE NONBULLOUS CONGENITAL ICHTHYOSIS BY THE EPIGALLOCATECHINE CUTANEOUS Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
33 PHASE I-II TRIAL OF METRONOMIC TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
34 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
35 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
36 A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
37 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
38 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
39 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
40 Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
41 A Randomized Controlled Trial of Clobetasol Propionate 0.05% Cream Versus Hydrocortisone 1% Cream in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
42 TREg Activation in the Treatment of the PELADE (Alopecia Areata). Double Blind Randomized Placebo Controlled Comparative Study Using Low Doses of IL2 Completed NCT02557074 Phase 3 IL2;placebo
43 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
44 Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM) Completed NCT01590238 Phase 3
45 A Two Stage Phase II Randomized Bilateral Comparison of Topical Targretin® Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
46 A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males Completed NCT00151515 Phase 3 minoxidil
47 A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
48 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
49 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia) Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
50 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3

Search NIH Clinical Center for Alopecia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


D-BIOTIN
Finasteride
Minoxidil

Cochrane evidence based reviews: alopecia

Genetic Tests for Alopecia

Genetic tests related to Alopecia:

# Genetic test Affiliating Genes
1 Alopecia 29

Anatomical Context for Alopecia

MalaCards organs/tissues related to Alopecia:

40
Breast, Skin, Lung, T Cells, Thyroid, Ovary, Prostate
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Alopecia:
# Tissue Anatomical CompartmentCell Relevance
1 Hair Hair Follicle Fetal Hair Placode Cells Affected by disease
2 Hair Hair Follicle Fetal Matrix Cells Affected by disease
3 Hair Dermal Papilla Guard Dermal Papilla Cells Affected by disease
4 Hair Hair Follicle Primary Hair Placode Cells Affected by disease

Publications for Alopecia

Articles related to Alopecia:

(show top 50) (show all 16456)
# Title Authors PMID Year
1
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. 61
31733195 2020
2
The different faces of mycosis fungoides: results of a single-center study. 61
31782525 2020
3
Off-label studies on apremilast in dermatology: a review. 61
30935262 2020
4
Exploring the potential of minoxidil tretinoin liposomal based hydrogel for topical delivery in the treatment of androgenic alopecia. 61
31741401 2020
5
Association of Autoimmune Regulator Gene Rs2075876 Variant, but Not Gene Expression with Alopecia Areata in Males: A Case-control Study. 61
31601134 2020
6
Lichen planopilaris and dyslipidemia: systematic review and meta-analysis. 61
32030783 2020
7
Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina. 61
32034775 2020
8
Local heroes or villains: tissue-resident memory T cells in human health and disease. 61
31969685 2020
9
Identification of a recurrent nonsense mutation in HR gene responsible for atrichia with papular lesions in two Kashmiri families. 61
32020700 2020
10
Practical Direct Immunofluorescence. 61
31990699 2020
11
Impact of alopecia areata on psychiatric disorders: A retrospective cohort study. 61
31279023 2020
12
Overlapping and Distinct FAS/FASLG Gene Polymorphisms in Alopecia Areata in an Iranian Population. 61
31741398 2020
13
Comparison of signal detection of tumour necrosis factor-α inhibitors using the Korea Adverse Events Reporting System Database, 2005-2016. 61
31673980 2020
14
Familial implications of autoimmune disease: Recurrence risks of alopecia areata and associated conditions in first-degree relatives. 61
31605426 2020
15
[Ichtyosiform erythroderma revealing a severe combined immunodeficiency]. 61
31973905 2020
16
Nevus psiloliparus: Newly described histopathologic features from transverse sections. 61
32034785 2020
17
Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia. 61
32037196 2020
18
Allergy to sunscreen and leave-on facial products is not a likely causative mechanism in frontal fibrosing alopecia: perspective from contact allergy experts. 61
31369143 2020
19
Novel drug delivery approaches for the management of hair loss. 61
32003262 2020
20
The importance of caveolins and caveolae to dermatology: Lessons from the caves and beyond. 61
31845391 2020
21
Scalp Avulsion Injuries and Replantation: Is Deep Temporal Artery an Alternate Option? 61
31397683 2020
22
Frontal fibrosing alopecia in Asians: a retrospective clinical study. 61
31605393 2020
23
"Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia". 61
31865282 2020
24
Design, synthesis, and biological activity of TLR7-based compounds for chemotherapy-induced alopecia. 61
31270708 2020
25
Contemporary Management of Alopecia: A Systematic Review and Meta-analysis for Surgeons. 61
31667549 2020
26
Chemotherapy-induced alopecia-A potentially preventable side effect with scalp cooling. 61
31585147 2020
27
Frontal fibrosing alopecia in males: demographics, clinical profile and treatment experience. 61
31566817 2020
28
Frontal fibrosing alopecia: histopathological, immunohistochemical and hormonal study of clinically unaffected scalp areas. 61
31566821 2020
29
Case of intractable scalp pustulosis with alopecia diagnosed with amicrobial pustulosis of the folds. 61
31691329 2020
30
Fully automated chip-based nanoelectrospray ionization-mass spectrometry as an effective tool for rapid and high-throughput screening of 5α-reductase inhibitors. 61
32008083 2020
31
'The psychosocial burden of alopecia areata and androgenetica': a cross-sectional multicentre study among dermatological out-patients in 13 European countries. 61
31465592 2020
32
Prolonged use of finasteride-induced gonadal sex steroids alterations, DNA damage and menstrual bleeding in women. 61
31967291 2020
33
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. 61
31461380 2020
34
Alopecia Areata is Associated with Atopic Diathesis; Results from a Population-Based Study of 51,561 Patients. 61
32036002 2020
35
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors. 61
30887250 2020
36
Protective effects of human umbilical cord blood‑derived mesenchymal stem cells against dexamethasone‑induced apoptotic cell death in hair follicles. 61
31894311 2020
37
Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study. 61
31622643 2020
38
Analysis of the gut microbiota in alopecia areata: identification of bacterial biomarkers. 61
31419351 2020
39
Female Androgenetic Alopecia: An Update on Diagnosis and Management. 61
31677111 2020
40
Trichologic response of platelet-rich plasma in androgenetic alopecia is maintained during combination therapy. 61
29580860 2020
41
Cell Enriched Autologous Fat Grafts to Follicular Niche Improves Hair Regrowth in Early Androgenetic Alopecia. 61
32020170 2020
42
Large-Scale Beard Extraction Enhances the Cosmetic Results of Scalp Hair Restoration in Advanced Androgenetic Alopecia in East Asian Men: A Retrospective Study. 61
31784942 2020
43
Autologous Activated Platelet-Rich Plasma (AA-PRP) and Non-activated (A-PRP) in Hair Growth: a retrospective, blinded, randomized evaluation in Androgenetic Alopecia. 61
32011196 2020
44
Ectopic Cushing's syndrome associated with a pheochromocytoma in a dog: a case report. 61
32014021 2020
45
Ultrasound-activated particles as CRISPR/Cas9 delivery system for androgenic alopecia therapy. 61
31901692 2020
46
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. 61
32031899 2020
47
A proposed mechanism for central centrifugal cicatricial alopecia. 61
29660185 2020
48
Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. 61
32016152 2020
49
Clinicopathologic and immunophenotypic characterization of lichen planopilaris and central centrifugal cicatricial alopecia: A comparative study of 51 cases. 61
31605498 2020
50
Cholestatic hepatitis with concomitant nephrotic syndrome due to late syphilis in an immunocompetent 32-year-old man. 61
32029514 2020

Variations for Alopecia

ClinVar genetic disease variations for Alopecia:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SASH1 NM_015278.5(SASH1):c.1849G>A (p.Glu617Lys)SNV Pathogenic/Likely pathogenic 156162 rs587781245 6:148855021-148855021 6:148533885-148533885
2 EMILIN2 , LPIN2 , METTL4 , MYL12A , MYL12B , MYOM1 , NDC80 , SMCHD1 , TGIF1 GRCh37/hg19 18p11.32-11.31(chr18:1345040-3479168)copy number loss Uncertain significance 523239 18:1345040-3479168

Expression for Alopecia

Search GEO for disease gene expression data for Alopecia.

Pathways for Alopecia

Pathways related to Alopecia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.22 GJA1 DSP CLDN1
2 10.3 GJA1 DSP CLDN1

GO Terms for Alopecia

Cellular components related to Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fascia adherens GO:0005916 8.62 GJA1 DSP

Biological processes related to Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.56 TP63 FOXN1 EDNRA AR
2 establishment of skin barrier GO:0061436 9.37 TP63 CLDN1
3 keratinocyte differentiation GO:0030216 9.33 TP63 FOXN1 DSP
4 prostate gland development GO:0030850 9.32 TP63 AR
5 thymus epithelium morphogenesis GO:0097536 8.96 FOXN1 AIRE
6 epidermis development GO:0008544 8.92 TP63 KRT14 FOXN1 DSP

Sources for Alopecia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....